Skip to main content

New story in Health from Time: A Cheap, Common Steroid Called Dexamethasone May Help Patients With Severe COVID-19, Study Says



A paper published Friday in the New England Journal of Medicine suggests a low-cost steroid may be a valuable treatment for severe COVID-19, building upon encouraging preliminary findings from last month.

In June, U.K. researchers reported that dexamethasone—a cheap, widely available steroid that can lower inflammation in the body—appeared to reduce by a third the risk of death among patients with severe COVID-19. U.K. practitioners began using dexamethasone the very same day the results were announced, but some medical experts were more guarded, arguing no conclusions should be made without seeing the trial’s full results.

Those results were published today in NEJM, and they seem to support what was announced last month. Dexamethasone did have a measurable benefit for COVID-19 patients sick enough to require respiratory support—but it had no such benefit, and even showed the potential for some possible harm, for patients with milder disease.

About 2,100 people hospitalized for confirmed or suspected COVID-19 were randomly assigned to receive a 10-day course of dexamethasone in addition to standard COVID-19 care, while about 4,300 received standard care alone. Around 16% of the patients (overall, both those given dexamethasone and those who were not) were receiving mechanical ventilation, 60% were receiving oxygen only and 24% were not getting any breathing support.

After 28 days, 482 patients taking dexamethasone had died, compared to about 1,110 of the patients not taking it. That means about 23% of the dexamethasone patients died, compared to about 26% of the other patients.

That may not seem like a terribly significant difference, but the researchers found a sizable benefit for the sickest patients in the sample: those requiring mechanical ventilation to survive. About 30% of these patients died on dexamethasone, compared to 41% of those not taking it. A smaller, but still significant, benefit was also seen for patients receiving oxygen without invasive ventilation.

Meanwhile, dexamethasone provided no benefit for patients who did not require breathing support. In fact, among patients with these milder cases, those taking dexamethasone were actually more likely to die—about 18% of them did, compared to 14% of those receiving standard care alone.

Logically, the anti-inflammatory drug seemed to work best in patients who had the most inflammation. Patients who had suffered symptoms for at least a week—and thus likely had developed some inflammatory lung damage—seemed to do better on the steroid than patients with newer symptoms, who may not have experienced much inflammation.

“It is likely that the beneficial effect of glucocorticoids [like dexamethasone] in severe viral respiratory infections is dependent on selection of the right dose, at the right time, in the right patient,” the researchers write in the paper. “High doses may be more harmful than helpful, as may such treatment given at a time when viral replication is paramount and inflammation is minimal.”

While the paper’s publication is an encouraging step forward, the preliminary research must still be validated and replicated by other investigators. The researchers also note that, because they aimed to release results as soon as possible to meet demand for new therapies, they did not collect some data on secondary and long-term outcomes.

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case....

New video by gymvirtual on YouTube

Rutina para adelgazar | Ejercicios para perder peso en casa ♥ ♥ LÉEME / DESPLIÉGAME ♥ ♥ Hola a todos, hoy os traigo una rutina de cardio de 25 minutos para quemar grasa y adelgazar en casa. En la web https://ift.tt/39VJREp encontraréis los calendarios de entrenamiento tanto para principiantes como para avanzados. Si quieres conseguir tú transformación en solamente 12 semanas, entra ya en http://www.pgv12.com y elige el PLAN PGV12 que más se adapte a ti. Nuestro lema: YO PUEDO CON TODO Los hashtags: #GymVirtual #YPCT #YoPuedoConTodo #PGV12 ♡♡ ¡SUSCRÍBETE! ♡♡ http://www.youtube.com/user/gymvirtual ................................................................................................................................. ♡♡ PLAN DE ENTRENAMIENTO + NUTRICIÓN 12 SEMANAS♡♡ http://www.pgv12.com ................................................................................................................................. ♡♡¡ECHA UN VISTAZO A NUESTRA TIENDA ONLINE! ♡♡ https://ift.tt/2Un...

New story in Health from Time: After Cruise Ships and Nursing Homes, Will Universities Be the Next COVID-19 Tinderboxes?

The fall semester has yet to begin, but student athletes training for the season can already be found on college campuses across the U.S. And so can COVID-19. Since the start of July there have been at least two outbreaks among student athletes, coaches, and staff—with 37 infected at the University of North Carolina (UNC) Chapel Hill and 22 at Boise State . Clusters of infection have been traced to college town bars popular with students. A common misconception is that young people with COVID-19 don’t die and therefore college re-openings pose little risk. Sadly, this isn’t the case. COVID-19 deaths in the young are rare, but they happen. Universities across the U.S. are mourning the loss of students in the lead-up to the school year, including Joshua Bush , a 30-year old nursing student at the University of South Carolina, Trevor Syphus Lee , a 27-year old senior at Utah Valley University, and Juan Garcia , a 21-year old Penn State undergraduate. One might imagine th...